Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)

被引：0
|
作者：
Ulf Schnetzke
Peter Fix
Baerbel Spies-Weisshart
Karin Schrenk
Anita Glaser
Hans-Joerg Fricke
Paul La Rosée
Andreas Hochhaus
Sebastian Scholl
机构：
[1] Universitätsklinikum Jena,Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II
[2] Universitätsklinikum Jena,Institut für Humangenetik
[3] Zentralklinik Bad Berka,Abteilung Internistische Onkologie und Hämatologie
来源：
Journal of Cancer Research and Clinical Oncology | 2014年 / 140卷
关键词：
AML; Relapse; FLT3; Cyclophosphamide; Stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1391 / 1397
页数：6
相关论文
共 50 条
  • [1] Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
    Schnetzke, Ulf
    Fix, Peter
    Spies-Weisshart, Baerbel
    Schrenk, Karin
    Glaser, Anita
    Fricke, Hans-Joerg
    La Rosee, Paul
    Hochhaus, Andreas
    Scholl, Sebastian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (08) : 1391 - 1397
  • [2] High dose cytarabine and cyclophosphamide (hAC) regimen for relapsed or refractory acute myeloid leukemia (AML): a retrospective monocentric analysis
    Fix, P.
    Fricke, H-J
    Spies-Weisshart, B.
    La Rosee, P.
    Hochhaus, A.
    Scholl, S.
    ONKOLOGIE, 2010, 33 : 138 - 139
  • [3] Safety and feasibility of outpatient high-dose cytarabine (HIDAC) and intermediate-dose cytarabine (IDAC) for consolidation therapy in acute myeloid leukemia (AML).
    Li, Wenhui
    Simondsen, Katherine
    Lee, Jamie
    Elharake, Maher
    Kubal, Timothy Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
    Nunnery, Sara
    Wang, Dorothy
    Tan, Marisela
    Fong, Richard
    Lo, Mimi Ming
    Olin, Rebecca L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia
    Li, Wenhui
    Richter, Katherine
    Lee, Jamie
    McCarthy, Kevin
    Kubal, Timothy
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1812 - 1818
  • [6] Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
    Scappini, Barbara
    Gianfaldoni, Giacomo
    Caracciolo, Francesco
    Mannelli, Francesco
    Biagiotti, Caterina
    Romani, Claudio
    Pogliani, Enrico M.
    Simonetti, Federico
    Borin, Lorenza
    Fanci, Rosa
    Cutini, Ilaria
    Longo, Giovanni
    Susini, Maria Chiara
    Angelucci, Emanuele
    Bosi, Alberto
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1047 - 1051
  • [7] Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML)
    Stuart, R. K.
    Stockerl-Goldstein, K.
    Cooper, M.
    Devetten, M.
    Herzig, R.
    Medeiros, B.
    Schiller, G.
    Wei, A.
    Acton, G.
    Rizzieri, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Foster, Matthew
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Scibilia, Richard
    Blanchard, Laura
    Frank, Cassiopeia
    Gallagher, Sean
    Matson, Melissa
    Pepin, Katherine
    Vaught, Lori
    Vogler, Nancy
    Gojo, Ivana
    Luznik, Leo
    Serody, Jonathan S.
    BLOOD, 2017, 130
  • [9] HIGH-DOSE MERCAPTOPURINE FOLLOWED BY INTERMEDIATE-DOSE CYTARABINE IN RELAPSED ACUTE-LEUKEMIA
    LOCKHART, S
    PLUNKETT, W
    JEHA, S
    RAMIREZ, I
    ZIPF, T
    CORK, A
    PINKEL, D
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 587 - 595
  • [10] Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Moore, Dominic
    McKinnon, Karen P.
    Wilkinson, Alec D.
    Mukhopadhyay, Rupkatha
    Mazziotta, Francesco
    Knaus, Hanna A.
    Foster, Matthew C.
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Webster, Jonathan A.
    Prince, Gabrielle T.
    DeZern, Amy E.
    Smith, B. Douglas
    Levis, Mark J.
    Montgomery, Nathan D.
    Luznik, Leo
    Serody, Jonathan S.
    Gojo, Ivana
    BLOOD CANCER DISCOVERY, 2021, 2 (06): : 616 - 629
12345